Updates are available Correction dated 2021-05-19
Click to view Correction: https://doi.org/10.1007/s12282-021-01255-8
-
Authors
Yamauchi, Chikako https://orcid.org/0000-0003-1799-8535
Yoshimura, Michio
Sekiguchi, Kenji
Hamamoto, Yasushi
Nakajima, Naomi
Sanuki, Naoko
Ogo, Etsuyo
Oguchi, Masahiko
Saji, Shigehira
Iwata, Hiroji
- License Information
-
More Information
Article History
Received: 5 October 2019
Accepted: 16 October 2019
First Online: 28 October 2019
Change Date: 19 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-021-01255-8
Compliance with ethical standards
:
: Chikako Yamauchi, Michio Yoshimura, Kenji Sekiguchi, Yasushi Hamamoto, Naomi Nakajima, Naoko Sanuki, Etsuyo Ogo, and Masahiko Oguchi have no conflict of interest. Hiroji Iwata reports grants and personal fees from Chugai, personal fees from AstraZeneca, personal fees from Daiichi Sankyo, grants and personal fees from Novartis, grants from MSD, grants and personal fees from Lilly, personal fees from Kyowa Hakko Kirin, personal fees from Pfizer, during the conduct of the study. However, Dr. Iwata confirms that the total fee from each company is not over the limited fee determined by JBCS. Shigehira Saji reports grants and personal fees (honoraria for lectures) from Eisai, grants and personal fees from Chugai, grants and personal fees from Astra Zeneca, grants and personal fees from Takeda, grants and personal fees from Novartis, grants and personal fees from Taiho, personal fees from Kyowahakko Kirin, personal fees from Pfizer, personal fees from Daiichi Sankyo, grants and personal fees from Nihon Kayaku, grants from Ono, outside the submitted work; Dr. Saji is executive board member of JBCRG and JBCS.
: This article does not contain any studies with human participants or animals performed by any of the authors.
